Michael Powell - 09 Jun 2026 Form 4 Insider Report for Bicara Therapeutics Inc. (BCAX)

Reporting relationship: Director
Issuer ticker: BCAX
Reported as of: 09 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jun 2026, 16:33:03 UTC
Prior SEC filing: 10 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Ryan Cohlhepp, Attorney-in-Fact

Key filing fact

Michael Powell filed Form 4 for Bicara Therapeutics Inc. (BCAX) on 10 Jun 2026.

Key facts

This page summarizes Michael Powell's Form 4 filing for Bicara Therapeutics Inc. (BCAX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Jun 2026, 16:33.

Change

Previous filing in this sequence was filed on 10 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001202793 Primary reporting owner

POWELL MICHAEL

Relationship: Director
Address: BICARA THERAPEUTICS INC., 116 HUNTINGTON AVENUE, SUITE 703, BOSTON
Signature: /s/ Ryan Cohlhepp, Attorney-in-Fact
Signature date: 10 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BCAX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +19,475
Change %
Price: $0.000000^*
Shares after: 19,475
Date: 09 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 19,475
Exercise price: $20.56
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying this stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc., subject to the Reporting Person's continued service on such vesting date.